Yissum, the Technology Transfer Company of the Hebrew University of Jerusalem and KYORIN Pharmaceutical Co., Ltd. (Tokyo, Japan), a subsidiary of KYORIN Holdings, Inc., which is engaged in the development and commercialization of prescription drugs, announced today a strategic collaboration in the discovery of respiratory drug therapies. Under the collaboration, KYORIN will sponsor a research program led by Prof. Francesca Levi-Schaffer of Hebrew University’s Institute of Drug Research in the School of Pharmacy, Faculty of Medicine and advance its own drug discovery research with the outcome from the program.
Prof. Levi-Schaffer specializes in the area of immunopharmacology for allergies. Her research focuses on mast cells and eosinophils, the main effector cells in allergic diseases such as asthma and atopic dermatitis. KYORIN focuses on R&D and commercialization of prescription drugs, and respiratory field is positioned as one of its franchises. In the new partnership, KYORIN and Prof. Levi-Schaffer will collaborate and screen for new drugs based on her expertise of allergic inflammation. As such, new potential targets for the suppression of asthma and other related indications will be identified. medici
For KYORIN, this international network with academic collaboration in research is significant and this opportunity to form cooperative research relationships for first-in- class drugs on various respiratory diseases will enhance our research capabilities for drug seeds discovery.
About KYORIN
Trusted among patients and professionals in the medical industry, KYORIN strives to be a company that contributes to the public health and is recognized as a one with social significance by improving its presence in specified therapeutic areas and through global discovery of novel drugs. KYORIN uses its sales and marketing strategy in focusing on respiratory, otolaryngology and urology, and concentrates resources on the innovative drug discovery activities in its own research, with supplementing and strengthening external drug discovery programs and technology platforms from academic institutions, venture start-ups, and domestic and international drug discovery companies, as open innovation partnership. For further information please visit www.kyorin-pharm.co.jp/en/
About Yissum
Yissum is the technology transfer company of The Hebrew University of Jerusalem. Founded in 1964, it is the third company of its kind to be established and serves as a bridge between cutting-edge academic research and a global community of entrepreneurs, investors, and industry. Yissum’s mission is to benefit society by converting extraordinary innovations and transformational technologies into commercial solutions that address our most urgent global challenges. Yissum has registered over 10,000 patents covering 2,800 inventions; licensed over 900 technologies and has spun out more than 135 companies. Yissum’s business partners span the globe and include companies such as Boston Scientific, Google, ICL, Intel, Johnson & Johnson, Merck, Microsoft, Novartis and many more. For further information please visit www.yissum.co.il
Related articles
Psychedelic Psilocybin Shows Promise as New OCD and Tourette’s Syndrome Treatment According to New Hebrew University Study
October 31, 2024 — Psilocybin, a psychedelic compound, shows promise as a potential treatment for obsessive-compulsive disorder (OCD) and Tourette’s Syndrome, according to a new study by Hadassah Hebrew University Medical Center. In the study, published in Molecular Psychiatry, the researchers
Revolutionizing Optical Imaging: Breakthrough Non-Invasive Technology for Imaging Through Scattering Media
October 18 — A groundbreaking study by researchers from the Institute of Applied Physics at the Hebrew University of Jerusalem, published in Nature Photonics, presents a revolutionary new method for non-invasive high-resolution imaging through highly scattering media. The team, led by Prof. Ori
New Arsenal of Bacterial Toxins for Fighting Infectious Diseases Discovered
October 21, 2024 — Researchers at the Hebrew University of Jerusalem have discovered a group of bacterial toxins that can kill harmful bacteria and fungi and could lead to new methods for fighting infections. According to the study published in Nature Microbiology, these toxins, found in over
